Danny Jones

And now you're outside playing with your kids.

And there's a cumulative effect of all of this stuff.

And sometimes we don't see the forest through the trees.

And so there was a dogma there.

And then over time, I think that dogma became accepted protocol.

But even back to your discussion about the GLP-1s, I would go back and say, why is your primary care so willing to reach for a GLP-1 or so willing to reach for insulin?

I can't tell you how many primary cares have told our patients that we treat now at WasteWell, they go, why talk to my primary care about peptides?

And they said, I don't know what you're talking about.

Or they said, peptides are dangerous.

I don't know anything about them.

They didn't train us on peptides.

You shouldn't be messing with peptides.

Insulin's a peptide.

The GLP-1 drug is a peptide.

You just know the peptides that insurance are covering.

And how do we decide what insurance covers?

You decide it because it's gone through the FDA.

And how do we decide what drugs make it through the FDA?

That's controlled by the big pharmaceutical companies because it costs over $250 million to bring a drug to market.

And the only way you're going to bring that drug to market is if you can patent the molecule.